Supplements and Featured Publications
2023 SOHO Meeting Reporter
Volume: 1
Issue: 1
Leveraging ctDNA as a Prognostic Biomarker in Breast Cancer
Volume: 1
Issue: 1
Reviewing Key Updates in the Realm of Breast Cancer
Volume: 1
Issue: 1
Examining Approaches Under Evaluation in ESR1+ ER+/HER2– Metastatic Breast Cancer
Volume: 1
Issue: 1
2023 ASH Meeting Reporter: Updates in CLL
Volume: 1
Issue: 1
2023 ASH Meeting Reporter: Updates in GVHD
Volume: 1
Issue: 1
Research Efforts Are Underway in the HCC Treatment Paradigm
Volume: 1
Issue: 1
Updates in Cholangiocarcinoma
Volume: 1
Issue: 1
This page is funded by Taiho Oncology, Inc. The faculty and publisher are solely responsible for this content. Taiho does not recommend or endorse the use of its products other than as described in the approved labeling. The content of this page is not medical advice and does not replace independent medical judgment.
Recent Updates on TROP2-Directed Antibody-Drug Conjugates in NSCLC
Volume: 1
Issue: 1
Research Efforts Are Underway in the Prostate Cancer Paradigm
Evaluating Key Clinical Updates in the Realm of Endometrial Cancer
Volume: 1
Issue: 1
Advances in Precision Medicine in Lung Cancer
Volume: 1
Issue: 1
Focus on Pathways: Liver Function Assessment in Hepatocellular Carcinoma
Volume: 1
Issue: 1
Novel Strategies Under Exploration in Pediatric Low-Grade Glioma
Volume: 1
Issue: 1
Updates on Progress Made in the HCC Treatment Paradigm
Volume: 1
Issue: 1
Leveraging ctDNA as a Prognostic Biomarker in CRC
Volume: 1
Issue: 1
ESMO 2023 Meeting Reporter: Updates in GU Cancers
Volume: 1
Issue: 1
Updates in TROP2-Directed and Other Novel ADCs in Breast Cancer
Volume: 1
Issue: 1
Mapping Advances Made in the Realm of Prostate Cancer
Volume: 1
Issue: 1
IRAK4 Inhibition Makes a Splash in B-Cell Malignancies
Volume: 1
Issue: 1
Considering Clinical Updates in Lung Cancer
Volume: 1
Issue: 1
Clinical Updates in Colorectal Cancer
Volume: 1
Issue: 1
Novel Approaches Under Evaluation in Gastrointestinal Stromal Tumors
Volume: 1
Issue: 1
Research Efforts Are Underway for Follicular Lymphoma
Volume: 1
Issue: 1
Novel Approaches Under Evaluation in Melanoma
Volume: 1
Issue: 1
ASCO 2023 Meeting Reporter: Updates in GU Cancers
Volume: 1
Issue: 1
Updates on Advances Made Across the Breast Cancer Treatment Paradigm
Volume: 1
Issue: 1
ASCO and EHA Meeting Reporter: Making the Most of New Data in Myeloproliferative Neoplasms
Volume: 1
Issue: 1
Mapping Advances Made With ADCs in Lung Cancer
Volume: 1
Issue: 1
Clinical Updates in Primary CNS Lymphoma
Volume: 1
Issue: 1
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
4
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
5